A total of 23 biopharmaceutical producers have committed capital to the vehicle, which will provide funding for the creation of new antibiotics.

Switzerland-based investment fund Antimicrobial Resistance (AMR) Action Fund has launched with almost $1bn in capital from biopharmaceutical companies to invest in developers of new antibiotics. AMR Action Fund is intended to operate as a partnership between 23 biopharmaceutical companies with the aim of bringing two to four new antibiotics to market by 2030. It is…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.